Summary
Electronic monitoring of the fetal heart rate during labor (EFM), originally designed to assess fetal stress and allow the early detection of the compromised fetus, has instead led to increasing maternal morbidity without decreasing fetal morbidity. The unintended consequences of this technologic advance have led to the creation of a pseudodisease and unwarranted intervention in response to its detection. Is it ethical to introduce a new technology without adequate assessment of its possible consequences? Are we about to repeat this (error resulting from the introduction of EFM?) There is increasing interest in monitoring the function of the newborn brain, to enable the early detection of subclinical seizures. The monitor may also be used for assessing brain function in older children and adults who are comatose or paralyzed and cannot appropriately respond to stimuli. Use of this amplitude-integrated electroencephalography (aEEG) in the newborn for detection of seizures and other brain abnormalities is not dissimilar to the use of electronic fetal heart rate monitoring. Whether seizures or subclinical seizures themselves cause harm to the developing nervous system is unclear. The effectiveness of medications for treatment of seizures in the newborn has not been established. Therefore, the consequences of introducing automated EEG for the detection of subclinical neonatal seizures are likely to be similar to the results of the introduction of EFM: creation of another pseudodisease, followed by unwarranted intervention, and increased legal liability. What are the ethics of continued approval and introduction of unevaluated technology? What is the wisdom of its use? Beware of the unintended consequences.
Key Words: Ethics of study design, fetal heart rate monitoring, aEEG, automated EEG
References
- 1.Hofmann B. The technological invention of disease. J Med Ethics. 2001;27:10–19. doi: 10.1136/mh.27.1.10. [DOI] [PubMed] [Google Scholar]
- 2.Fisher ES, Welch HG. Avoiding the unintended consequences of growth in medical care: how might more be worse? JAMA. 1999;281:446–453. doi: 10.1001/jama.281.5.446. [DOI] [PubMed] [Google Scholar]
- 3.Clancy RR. Summary proceedings from the Neurology Group on Neonatal Seizures. Pediatrics. 2006;117:S23–S27. doi: 10.1542/peds.2005-0620D. [DOI] [PubMed] [Google Scholar]
- 4.Graham EM, Peterson SM, Christo DK, Fox HE. Intrapartum electronic fetal heart rate monitoring and the prevention of perinatal brain injury. Obstet Gynecol. 2006;108:656–666. doi: 10.1097/01.AOG.0000230533.62760.ef. [DOI] [PubMed] [Google Scholar]
- 5.Royal College of Obstetricians and Gynaecologists . The use and interpretation of cardiotocography in intrapartum fetal surveillance. London: RCOG Press; 2001. The use of electronic fetal monitoring. [Google Scholar]
- 6.Alfirevic Z, Devane D, Gyte GM. Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database Syst Rev. 2006;3:CD006066–CD006066. doi: 10.1002/14651858.CD006066. [DOI] [PubMed] [Google Scholar]
- 7.Nelson K. Can we prevent cerebral palsy? N Engl J Med. 2003;349(18):1765–1769. doi: 10.1056/NEJMsb035364. [DOI] [PubMed] [Google Scholar]
- 8.Greene MF. Obstetricians still await a deus ex machina. N Engl J Med. 2006;355:2247–2248. doi: 10.1056/NEJMe068176. [DOI] [PubMed] [Google Scholar]
- 9.Freeman JM. The use of amplitude-integrated electroencephalography: beware of its unintended consequences. Pediatrics. 2007;119:615–617. doi: 10.1542/peds.2006-3650. [DOI] [PubMed] [Google Scholar]
- 10.Rosen I. the physiological basis for continuous electroencephalogram monitoring in the neonate. Clin Perinatol. 2006;33:593–611. doi: 10.1016/j.clp.2006.06.013. [DOI] [PubMed] [Google Scholar]
- 11.Greisen G. Brain monitoring in the neonate: the rationale. Clin Perinatol. 2006;33:613–618. doi: 10.1016/j.clp.2006.06.001. [DOI] [PubMed] [Google Scholar]
- 12.Rogawski MA. Point—counterpoint: do interictal spikes trigger seizures or protect against them? Epilepsy Curr. 2006;6:197–198. doi: 10.1111/j.1535-7511.2006.00144.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Staley KJ, Dudek FE. Interictal spikes and epileptogenesis. Epilepsy Curr. 2006;6:199–202. doi: 10.1111/j.1535-7511.2006.00145.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Avoli M, Biagini G, de Curtis M. Do interictal spikes sustain seizures and epileptogenesis? Epilepsy Curr. 2006;6:203–207. doi: 10.1111/j.1535-7511.2006.00146.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Murray DM, Ryan CA, Boylan GB, et al. Prediction of seizures in asphyxiated neonates: correlation with continuous videoelectroencephalographic monitoring. Pediatrics. 2006;118:41–46. doi: 10.1542/peds.2005-1524. [DOI] [PubMed] [Google Scholar]
- 16.Freeman AD, Freeman JM. No-fault cerebral palsy insurance: an alternative to the obstetrical malpractice lottery. J Health Polit Policy Law. 1989;14:707–718. doi: 10.1215/03616878-14-4-707. [DOI] [PubMed] [Google Scholar]
- 17.Shankaran S, Laptook A. Challenge of conducting trials of neuroprotection in the asphyxiated term infant. Semin Perinatol. 2003;27:320–332. doi: 10.1016/S0146-0005(03)00047-8. [DOI] [PubMed] [Google Scholar]
- 18.Gunn AJ, Battin M, Gluckman PD, Gunn TR, Bennet L. Therapeutic hypothermia: from lab to NICU. J Perinat Med. 2005;33:340–346. doi: 10.1515/JPM.2005.061. [DOI] [PubMed] [Google Scholar]
- 19.Goodman SN. Ethics and evidence in clinical trials. Clin Trials. 2005;2:195–196. doi: 10.1191/1740774505cn083ed. [DOI] [PubMed] [Google Scholar]
- 20.Hlatky MA, Owens DK, Sanders GD. Cost-effectiveness as an outcome in randomized clinical trials. Clin Trials. 2006;3:543–551. doi: 10.1177/1740774506073105. [DOI] [PubMed] [Google Scholar]
- 21.Gray AM. Cost-effectiveness analysis alongside randomized clinical trials. Clin Trials. 2006;3:538–542. doi: 10.1177/1740774506073108. [DOI] [PubMed] [Google Scholar]
- 22.U.S. Food and Drug Administration. Innovation or stagnation? Challenge and opportunity on the critical pathway to new medical products. FDA, 2004 [Available at: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf].
- 23.Botkin JR, Clayton EW, Fost NC, et al. Newborn screening technology: proceed with caution. Pediatrics. 2006;117:1793–1799. doi: 10.1542/peds.2005-2547. [DOI] [PubMed] [Google Scholar]
